COMMUNIQUÉS West-GlobeNewswire

Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
07/08/2026
-- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility [...]
Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
07/08/2026
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity [...]
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
07/08/2026
Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin ® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year Quarterly GAAP net income available to common [...]
Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results
07/08/2026
Reports second quarter 2026 total revenue of $8.1 million , representing 11% growth compared to the second quarter of 2025 Achieved a significant milestone with the 200th Growth Direct system placed globally; placed [...]
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
07/08/2026
FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters. Remaining item relates to manufacturer certification for a luer lock [...]
Vireo Growth Receives Regulatory Approval and Completes Acquisition of PharmaCann Colorado Retail Assets
07/08/2026
MINNEAPOLIS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform, today announced that it has received [...]
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
07/08/2026
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
07/08/2026
FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced [...]
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
07/08/2026
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May [...]
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
07/08/2026
PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update
07/08/2026
TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/08/2026
SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Financière de Tubize - Rapport financier semestriel 2026
07/08/2026
Rapport financier semestriel 2026 Information réglementée - 1 août 2026 Le conseil d’administration de la Financière de Tubize a établi le rapport financier semestriel 2026. Ce rapport est disponible sur le site [...]
Financière de Tubize - 2026 half-year financial report
07/08/2026
Half-year financial report 2026 Regulated information 1 August 2026 The board of directors of Financière de Tubize has established the 2026 half-year report. This report is available on the website www.financiere-tubize [...]
Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years
07/08/2026
MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus Approval further strengthens MVA-BN’s position in supporting global [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
07/08/2026
Tokyo, Japan and Cambridge, UK, 7 August 202 6 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter ended 30 June [...]
National Health Sanitary Association Announces United Nations Procurement and Partnership Registration
07/08/2026
Washington State-based public health organization expands international cooperation framework for disease prevention, health education, humanitarian assistance and community health development. WASHINGTON, Aug. 07, 2026 [...]
Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering
07/08/2026
THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced [...]
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
07/08/2026
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop [...]

Pages